Table 3.

Cox proportional hazard regression model for incident ALF according to the tertiles of each insulin resistance index.

	Total Cases, n	New Onset ALF Cases, n	Person-Years of Follow-Up	Incidence Rate Per 1000 Person-Years	Unadjusted		Model 1		Model 2		Model 3
					HR (95% CI)	p	HR (95% CI)	p	HR (95% CI)	p	HR (95% CI)	p
	1368	260	19,939.4	13.0
METS-IR
T1 (<41.15)	456	99	6443.1	15.4	1 (reference)		1 (reference)		1 (reference)		1 (reference)
T2 (41.15–45.70)	455	91	6670.2	13.6	0.89 (0.67–1.19)	0.429	0.82 (0.58–1.15)	0.250	0.81 (0.58–1.14)	0.235	0.82 (0.58–1.15)	0.250
T3 (≥45.71)	457	70	6826.1	10.3	0.67 (0.49–0.90)	0.009	0.63 (0.40–0.99)	0.047	0.60 (0.38–0.95)	0.030	0.59 (0.37–0.94)	0.026
TyG index
T1 (<8.84)	456	98	6514.4	15.0	1 (reference)		1 (reference)		1 (reference)		1 (reference)
T2 (8.84–9.26)	455	93	6645.0	14.0	0.93 (0.70–1.24)	0.620	0.88 (0.65–1.20)	0.410	0.92 (0.68–1.26)	0.616	0.96 (0.70–1.31)	0.774
T3 (≥9.27)	457	69	6780.0	10.2	0.68 (0.50–0.92)	0.014	0.66 (0.47–0.92)	0.013	0.73 (0.52–1.03)	0.071	0.74 (0.53–1.04)	0.087
HOMA-IR
T1 (<1.91)	457	84	6685.6	12.6	1 (reference)		1 (reference)		1 (reference)		1 (reference)
T2 (1.91–2.65)	456	82	6648.3	12.3	0.98 (0.73–1.33)	0.919	1.08 (0.78–1.48)	0.654	1.07 (0.77–1.47)	0.697	1.16 (0.81–1.54)	0.505
T3 (≥2.65)	455	94	6605.5	14.2	1.15 (0.86–1.55)	0.347	1.04 (0.75–1.44)	0.811	1.02 (0.74–1.40)	0.920	1.04 (0.75–1.44)	0.826

Model 1: adjusted for sex, age, body mass index, physical activity, smoking status, drinking status, total energy intake, and vitamin E intake. Model 2: adjusted for variables used in Model 1 plus mean blood pressure, serum total cholesterol level, and serum CRP level. Model 3: adjusted for variables used in Model 2 plus serum ALT level. Abbreviations: ALF, advanced liver fibrosis; HR, hazard ratio; CI, confidence interval; METS-IR, metabolic score for insulin resistance; TyG, triglyceride-glucose; HOMA-IR, homeostatic model assessment for insulin resistance; CRP, C-reactive protein; ALT, alanine aminotransferase.